Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Dynavax Technologies Corporation (Nasdaq: DVAX)

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; a therapy for non-Hodgkin's lymphoma in Phase 2 and a therapy for metastatic colorectal cancer in Phase 1. Our pre-clinical asthma and COPD programs are partnered with AstraZeneca. Funding for our colorectal cancer program and our preclinical programs in hepatitis B and hepatitis C therapies and for an influenza vaccine has been provided by Symphony Dynamo, Inc. and the NIH, and these programs represent future partnering opportunities. *


Period Start 1996-08-01 established
  Group Dynavax (Group)
Products Industry pharmaceutical
  Industry 2 vaccine
Region Region Berkeley, CA
  Country United States (USA)
  Street 2929 Seventh Street
Suite 100
  City 94710 Berkeley, CA
  Tel +1-510-848-5100
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency USD
  Annual sales 14,655,000 (revenues, total, consolidated (2005) 2005-12-31)
  Profit -20,555,000 (2005-12-31)
  Cash 75,110,000 (2005-12-31)
    * Document for �About Section�: 
Record changed: 2020-05-04


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Dynavax (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top